Table 1– Distribution of the main sociodemographic and clinical characteristics in subjects with current physician-diagnosed asthma according to ADRB2 Gly16Arg genotype in the European Community Respiratory Health Survey (ECRHS) II population#
Gly/GlyGly/ArgArg/Argp-value
Subjects221277106
Age yrs42.6±7.642.2±7.241.8±7.40.65
Age of onset <16 yrs84 (38.9)13 (49.1)44 (41.5)0.07
Females127 (57.2)168 (60.6)61 (57.6)0.73
Body mass index kg·m−226.4±5.826.0±5.025.8±5.20.55
Smoking
 Current65 (29.7)79 (28.8)25 (23.8)0.16
 Former71 (32.4)66 (24.1)32 (30.5)
 Never83 (37.9)129 (47.1)48 (45.7)
Inhaled SABAs126 (58.3)160 (59.5)72 (67.9)0.23
Inhaled LABAs38 (17.5)41 (14.9)21 (19.8)0.48
Inhaled steroids107 (49.5)120 (43.6)54 (50.9)0.29
FEV1 % pred
 At ECRHS I98.04±18.197.6±17.294.7±18.00.25
 At ECRHS II96.80±16.397.6±15.895.1±16.50.42
BHR64 (45.7)95 (55.6)41 (64.1)0.04
Total IgE >100 kU·L−197 (44.9)148 (54.2)59 (55.7)0.07
Chronic cough or phlegm56 (25.9)80 (29.3)30 (29.1)0.69
Allergic rhinitis111 (50.7)168 (61.1)58 (54.7)0.06
  • Data are presented as n, mean±sd or n (%), unless otherwise stated. SABA: short-acting β2-agonist; LABA: long-acting β2-agonist; FEV1: forced expiratory volume in 1 s; % pred: % predicted; BHR: bronchial hyperresponsiveness; Ig: immunoglobulin. Bold indicates statistically significant p-values. #: n=604.